FDA clears Cardiac Science's advanced AED for professionals:
This article was originally published in Clinica
Executive Summary
The US FDA has given Cardiac Science clearance to market what the Irvine, California firm claims is a technologically advanced automated external defibrillator (AED) designed for use by medical and emergency rescue professionals. The Powerheart AED G3 PRO is unique in that it displays the victim's heart rhythm on a built-in high resolution colour electrocardiogram display and gives users the option of delivering defibrillation shocks either semi-automatically or manually during the emergency treatment of victims of sudden cardiac arrest. The device has a suggested list price of $3,995.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.